Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection
Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection
复制标题
DOI：
10.1002/jmv.26698
复制
发表时间：
2020-12-17
影响因子：
12.7
通讯作者：
Kurniawan, Andree
中科院分区：
文献类型：
--
作者：
Hariyanto, Timotius Ivan;Kurniawan, Andree
2019冠状病毒病（COVID-19）对生活的各个方面造成了重大影响，死亡病例仍在增加。因此，确定降低疾病严重程度的潜在治疗是重要的。目前，关于托珠单抗作为COVID-19感染治疗药物的有效性的数据仍然存在矛盾。本研究旨在提供关于托珠单抗在减少COVID-19感染生物标志物方面的潜在益处的明确证据。我们使用与我们的目标相关的特定关键词系统地检索了PubMed Central数据库，直至2020年7月24日。检索了所有发表的关于COVID-19和托珠单抗的文章。我们的分析共纳入了9项研究，共计577例患者。我们的荟萃分析显示，托珠单抗治疗与C反应蛋白降低相关（平均差异[MD]：-106.69 mg/L [95%置信区间[CI]：-146.90，-66.49 mg/L]，p < .00001; I-2 = 98%，随机效应建模），d-二聚体（MD：-3.06 mg/L [95% CI：-5.81，-0.31 mg/L]，p = 0.03; I-2 = 98%，随机效应建模），铁蛋白（MD：-532.80 ng/ml [95% CI：-810.93，-254.67 ng/ml]，p = .0002; I-2 = 25%，随机效应建模），降钙素原（MD：-0.67 ng/ml [95% CI：-1.13，-0.22 ng/ml]，p = 0.004; I-2 = 92%，随机效应模型]，淋巴细胞计数水平增加（MD：0.36 × 10（3）/μ l [95% CI：0.18，0.54 × 10（3）/μ l]，p <0.0001; I-2 = 88%，随机效应建模）。托珠单抗的给药可有效减少COVID-19感染的生物标志物。
Coronavirus disease 2019 (COVID-19) has caused a significant impact on all aspects of life, with the number of death cases still increasing. Therefore, identification of potential treatment for reducing the severity of the disease is important. Currently, the data regarding the effectiveness of tocilizumab as treatment agents for COVID-19 infection is still conflicting. This study aims to give clear evidence regarding the potential benefit of tocilizumab in reducing the biomarkers of COVID-19 infection. We systematically searched the PubMed Central database using specific keywords related to our aims until July 24th, 2020. All articles published on COVID-19 and tocilizumab were retrieved. A total of 9 studies with a total of 577 patients were included in our analysis. Our meta-analysis showed that tocilizumab treatment is associated with reduction of C-reactive protein (mean difference [MD]: -106.69 mg/L [95% confidence interval [CI]: -146.90, -66.49 mg/L], p < .00001; I-2 = 98%, random-effect modeling), d-dimer (MD: -3.06 mg/L [95% CI: -5.81, -0.31 mg/L], p = .03; I-2 = 98%, random-effect modeling), Ferritin (MD: -532.80 ng/ml [95% CI: -810.93, -254.67 ng/ml], p = .0002; I-2 = 25%, random-effect modeling), procalcitonin (MD: -0.67 ng/ml [95% CI: -1.13, -0.22 ng/ml], p = .004; I-2 = 92%, random-effect modeling], and increment in the levels of lymphocyte count (MD: 0.36 x 10(3)/mu l [95% CI: 0.18, 0.54 x 10(3)/mu l], p < .0001; I-2 = 88%, random-effect modeling). Administration of tocilizumab is effective in reducing the biomarkers of the COVID-19 infection.